Foresee Pharmaceuticals Co., Ltd.

This phase 3 trial tests a new formulation of leuprolide (FP-001) given as two injections six months apart in 93 children with central precocious puberty—a condition where puberty starts too early. The goal is to see if it can safely pause puberty by keeping hormone levels low. I…